Icatibant (Firazyr)

Icatibant (Firazyr) is covered only for FDA‑approved treatment of acute hereditary angioedema (HAE) attacks due to C1‑INH deficiency (Type I or II) and is not authorized for non‑FDA uses. Coverage requires baseline labs (functional C1‑INH <50% and low serum C4), prescription by or in consultation with an HAE specialist/allergist‑immunologist, dosing ≤30 mg SC no more than three times daily, 12‑month approval periods, and reauthorization requires prior icatibant use with documented favorable clinical response.

"Treatment of acute attacks of hereditary angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.